Welcome Message – Panos Englezos, TIF President
Milestones and Current Initiatives of the Thalassaemia International Federation – Dr. Androulla Eleftheriou, TIF Executive Director

• A fresh glance at the national and provincial births of thalassemia new cases in Iran from 2001 to 2006, M.H. Dehshal
• Results from national thalassemia prevention program in Iran 2007-2009, M. H. Dehshal
• Frequency of Haemoglobinopathies: A Single Centre Cross Sectional Study from Islamabad, Pakistan, U. Waheed
• Haemoglobinopathy Carrier Prevalence in The United Arab Emirates: First Analysis of The Dubai Health Authority Premarital Screening Program Results, K. Belhoul
• Haemoglobinopathies in Hatay, V. V. Tas
• Effectiveness and feasibility of transabdominal chorionic villous sampling procedure for prenatal diagnosis of â-thalassaemia in a Muslim majority community of Pakistan, S. Erum
• Epidemiology and burden of alpha-thalassaemia, F. Piel
• Global migration and the changing distribution of sickle haemoglobin, F. Piel
• Individuals understanding of blood genetic disorders and pre-marital screening as a method of prevention in Saudi Arabia, M. el Hazmi
• The multiregional Italian Thalassemia Registry: patient’s population changes and related iron chelation approach, L. Mangiarini
• HbS: an emerging problem in Italy. The Latium example, M. P. Cappabianca
• Implementation of prevention and control program for thalassemia at Maria Teresa Hospital, Lao PDR., K. Sanchaisuriya
• Multi-stakeholder, multi-pronged strategies for thalassemia management, control & prevention: experiences from Bangalore, India, S. Gambhir
• The role of being ‘carrier couples’ for Transfusion Dependent Thalassemia Major (TDTM) in reproductive behavior, Mazandaran, 2012, M. Kosaryan

• The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background, M. Neishabury
• An overview of CFSD achievements in the field of Thalasaemia prevention and control in Islamic Republic of Iran, F. H. Bahremani
• Pharmacologic Immunoablation by Reduced Toxicity conditioning and stem cell transplantation in high risk thalassemia ; A safe approach to disease control, S. Hongeng
• Hand Hygiene Audit at Dubai Thalassemia Centre, M. L. Bakir

• Cardiac Iron Overload and Heart Function by CMR In Different Phenotypic Groups of Thalassemia Major Patients., A. Pepe
• N-terminal fragment of proBNP is a marker of high cardiac output cardiomyopathy evaluated by CMR in thalassemia syndromes., A. Pepe
• N-terminal fragment of proBNP is a marker of risk for right ventricular dysfunction and cardiac complications in thalassemia major., A. Pepe
• Direct and indirect involvement of HCV infection in the pathogenesis of myocardial fibrosis in thalassemia major, A. Pepe
• Asymmetric Dimethylarginine Levels In Children With ¦¢-Thalassemia And Their Correlations To Tricuspid Regurgitant Jet Velocity, M. El-Shanshory
• Cardiac iron measurement and iron chelation therapy in patients with ¦Â thalassaemia major: Experience from Taiwan, M. Yao Lu
• Cytoplasmic sequestration of heat shock protein 70 (Hsp70) by excess of free I±-globin promotes ineffective erythropoiesis in I²-Thalassemia major (TM), J.A. Ribeil
• Rare diseases reference Centers in order to improve thalassemia patient’s care, I. Thuret
• A multi-ethnic multi-national approach to Ethical approval of clinical trials involving Thalassaemia patients, V. Giannuzzi

• «The DEEP Project», S. Missouri-Khetab
• Iron status and hepcidin serum level in newly diagnosed severe B thalassemia: time to start delivering iron chelation therapy – a longitudinal study, S. Susanah
• The comparison of side effects and iron excretion in urine by two brands of deferoxamine( Desfonak® and Desferal® ) in major Thalassemia patients, P. Eshghi

• Growing Up With Thalassemia Major: Vocational and Social Achievements, K. Belhoul
• Quality of Life in Adult Patients with Thalassemia Major: A Single Centre Experience, M. Ali

• Utility of the multivariate approach in predicting the â-thalassemia intermedia or major types in Iranian patients, M. Banan
• Beta-Thalassemia Intermedia in Dubai: Molecular Genetics and Clinical Phenotype, M.S. Eldin
• Genetic Prognosticator for management of beta Thalassaemia patients without blood transfusion, S. Hussain Ansari
• Molecular Analysis of Beta Thalassaemia Intermedia in Sri Lanka, S. Perera

• Misdiagnosis of Hb D-Punjab/â-thalassemia is a potential pitfall in hemoglobinopathy screening programs: a case report, M. L. Bakir
• ACE-536 Mitigates Ineffective Erythropoiesis and Corrects Anemia in beta-thalassemia, R. Kumar
• Non-invasive Prenatal Diagnosis of Sickle Cell Disease by Massively Parallel Amplicon Sequencing, S. Henderson

• The relationship of chelation therapy and sera levels of parathormone and osteocalcin and bone density in thalassemia major in east delta of Egypt, U. El safy
• Acute Effects of Blood transfusion on Pituitary Gonadal Axis and Sperm Parameters in Young Males with Sickle Cell Disease (SCD);A Pilot Study, M. Yassin
• Acute Effects of Blood transfusion on Pituitary Gonadal Axis and Sperm Parameters in Adolescents and Young Males with Thalassaemia Major A Pilot Study, M. Yassin
• Evaluation of glycemic abnormalities in Beta Thalassemia major using Continous glucose monitoring system and oral glucose tolerence test, M. Yassin
• Effects of the Anti Rank Ligand Denusomab On Beta Thalassemia Major-Induced Osteoporosis, M. Yassin

• An automatic method for myocardial T2* curve fitting in thalassemia patients with severe iron overload, A. Pepe
• Audit and Re-Audit of Mean Annual Pre-Transfusion Hb Level of Patients with B Thalassemia Major at Dubai Thalassemia Centre, M. L. Bakir
• Predictors of liver disease in patients with thalassemia, G. Lavranos
• Evaluation of the s-303 treatment system for processing of red blood cell components for thalassemia major patients, N. Mufti
• Fludarabine/Treosulfan/Thiotepa/ATG Conditioning Leads to Earlier Engraftment and Higher Donor Chimerism than Busulfan/Cyclophosphamide, and Expands the Donor Pool by Enabling the Use of Mismatched and Unrelated Donors for Transplantation in Haemoglobinopathies., J. de la Fuente

• Myocardial and hepatic iron overload in sickle/thalassemia patients of Italian origin. A. Pepe
• Correlation of Acute Chest Syndrome with e-NOS, ARG1 and GSNOR gene polymorphisms in Omani Sickle cell patients, A. Pathare
• Pulmonary hypertension in sickle cell disease: correlation with serum brain natriuretic peptide concentrations, A. Pathare
• A Modified Technique of Manual Partial Exchange Transfusion in Sickle Cell Disease, H. Dewedar
• A Comprehensive Care in Sickle Cell Disease can Improve the Quality of Life Outcomes, S. Al Jaouni
• Transcranial Doppler and Brain Magentic Resonance Imaging in Sickle Cell Disease Patients with Elevated Fetal Hemoglobn, A. D. Adekile

• Deferasirox reduces iron overload with a manageable safety profile in pediatric patients with non-transfusion-dependent thalassemia (NTDT): Results from the THALASSA study, V. Viprakasit
• Non-transferrin bound iron revisited: now that its potential toxicity is established, how can its measurement help to guide chelation, V. Berdoukas
• Pharmacogenetic Evaluation for Clinical Response to Standard Once Daily Dose of a Novel Oral Iron Chelator; Deferasirox in Thai Thalassemia Patients, S. Rodmai

• Living Beyond Odds: The Educational attainment and Employment Status of Children and Adults with Thalassemia in India, S. Singh
• Patient Involvement in Building a Thalassemia Self-Management Smartphone Application Using Consensus Methodology with the Aim of Improving Long-term care, K. Taha
• Predicting Adherence to Iron Chelation Therapy in Thalassaemia and Sickle Cell Disease, K. Anie

• Increasing access to cure for thalassemia: review of infectious complications in 88 thalassemia matched-related bone marrow transplants performed without positive pressure room or centralized HEPA filtration, M. El Missiry
• Heart and Liver Magnetic Resonance Imaging T2* for assessing myocardial and hepatic iron overload in thalassemia major, P. A. Wahidiyat
• Technology Insight: MRI T2* for tissue iron quantification, T. He

• A novel Procedure for Preparing Pluripotent Haematopietic Stem Cells from Unmoblized Peripheral Blood via a Process of Retrodifferentiation for the Treatment of Hematological Conditions, I.Abuljadayel
• Reducing Length of Stay for Patients Receiving Chronic Blood Transfusion, S. Darwazeh
• Human stem cell derived red blood cells for the treatment of Beta Thalassemia Major, J.C. Mountford

• Movement abnormalities in the left ventricle of thalassemia major patients, A. Pepe
• Heart Rate Variability In Patients With Thalassemia Major Without Clinical Involvement Of Cardiovascular System, M. Saravi

• Therapeutic Benefit of Small Molecule inhibitors of MEK in Reducing Sickle Red cell Adhesion and Vaso-Occlusion in vivo, R. Zennadi
• National Neonatal Screening Program for Sickle and Non-Sickle Hemoglobinopathies In United Arab Emirates, H. Al Hosani
• Therapeutic Phlebotomy in Children with Sickle Cell Anemia, Stroke, and Iron Overload: The SWiTCH Clinical Trial, B. Aygun

• First report of the spectrum of  o-globin gene mutations in Omani subjects, A. Pathare
• Diagnosis of Unusual Alpha Globin Gene Mutations Using a Novel Molecular Approach, S. Daar
• Molecular and cellular analysis of three novel á2-globin gene promoter mutations (HBA2:c.-59C>T), (HBA2:c.-81C>A) and (HBA2:c.-91G>A) reveal varying patterns of transcriptional and translational activities, R. Ghassemifar
• Interference of d-globin genes in the diagnosis of B-thalassemia trait, M. P. Cappabianca

• Decreasing BCL11A levels additively increase HbF production in adult B-thalassemia/HbE erythroblasts, O. Sripichai
• Experimental insertion of a 2nd TATA binding protein site at the position 73 prior to the translation initiation site significantly compensates the activity loss of the endogenous HBA2 TATA binding protein site, R. Ghassemifar
• Experimental characterization of transcriptional activator and suppressor elements sites within the á-globin core and proximal promoter region, R. Ghassemifar
• Restoration of correct splicing of IVS2-654 â-thalassemic pre-mRNA by modified antisense U7 snRNA lentiviral vector, N. Jearawiriyapaisarn